Dr. Mark Levis, M.D.
Medical Oncology (Medical Oncology Physician)
600 N Wolfe St
Baltimore, MD 21287
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 149
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: University of California, San Francisco School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MD license D52391 -
Internal Medicine Physician
MD license D52391
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Johns Hopkins Hospital, the Baltimore, MD
- Sibley Memorial Hospital Washington, DC
Medical groups
- Johns Hopkins University (2,909 clinicians)
- Johns Hopkins University (197 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 149
- Services billed
- 629
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 275 | 61 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 186 | 33 |
| Bone marrow, smear interpretation | 41 | 40 |
| Established patient office or other outpatient visit, 30-39 minutes | 31 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Valacyclovir (valacyclovir hcl) Other prescribers in Baltimore, MD | 108 |
| Xospata (gilteritinib fumarate) | 92 |
| Tibsovo (ivosidenib) | 48 |
| Tramadol Hcl Other prescribers in Baltimore, MD | 39 |
| Venclexta (venetoclax) | 31 |
| Idhifa (enasidenib mesylate) | 28 |
| Sprycel (dasatinib) | 24 |
| Famotidine Other prescribers in Baltimore, MD | 24 |
| Pantoprazole Sodium Other prescribers in Baltimore, MD | 23 |
| Levothyroxine Sodium Other prescribers in Baltimore, MD | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 32 payments worth $59,190 in total to this clinician.
| Astellas Pharma Inc | $15,734 |
|---|---|
| Astellas Pharma US Inc | $15,177 |
| Daiichi Sankyo Inc. | $12,853 |
| Astellas Pharma Europe LTD | $6,090 |
| Sumitomo Pharma America, Inc. | $6,020 |
| Janssen Scientific Affairs, LLC | $2,517 |
| Syndax Pharmaceuticals, Inc. | $800 |
| Consulting Fee | $41,393 |
|---|---|
| Travel and Lodging | $11,991 |
| Compensation for services other than consulting (speaking, faculty) | $5,504 |
| Food and Beverage | $302 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma Inc Oct 4, 2025 | Travel and Lodging Xospata · Oncology · travel to Kobe, Japan | $9,029 |
| Daiichi Sankyo Inc. Mar 19, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $6,250 |
| Astellas Pharma US Inc Dec 9, 2025 | Consulting Fee Xospata · Oncology | $6,230 |
| Astellas Pharma Europe LTD Jul 28, 2025 | Consulting Fee Xospata · Oncology | $6,090 |
| Astellas Pharma Inc Nov 28, 2025 | Compensation for services other than consulting (speaking, faculty) Xospata · Oncology | $5,504 |
| Astellas Pharma US Inc Apr 10, 2025 | Consulting Fee Xospata · Oncology | $4,050 |
| Astellas Pharma US Inc Jul 8, 2025 | Consulting Fee Cresemba · Infectious Diseases | $3,825 |
| Sumitomo Pharma America, Inc. Aug 21, 2025 | Consulting Fee | $3,440 |
| Sumitomo Pharma America, Inc. Aug 21, 2025 | Consulting Fee | $2,580 |
| Janssen Scientific Affairs, LLC Sep 23, 2025 | Consulting Fee | $2,503 |
All 24 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Dec 23, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $1,250 |
| Syndax Pharmaceuticals, Inc. Dec 22, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $800 |
| Astellas Pharma US Inc Dec 9, 2025 | Consulting Fee Xospata · Oncology | $6,230 |
| Astellas Pharma US Inc Dec 9, 2025 | Travel and Lodging Xospata · Oncology · travel to Orlando, FL | $29.67 |
| Astellas Pharma Inc Nov 28, 2025 | Compensation for services other than consulting (speaking, faculty) Xospata · Oncology | $5,504 |
| Astellas Pharma Inc Oct 11, 2025 | Travel and Lodging Xospata · Oncology · travel to Kobe, Japan | $954 |
| Astellas Pharma Inc Oct 5, 2025 | Travel and Lodging Xospata · Oncology · travel to Kobe, Japan | $233 |
| Astellas Pharma Inc Oct 4, 2025 | Travel and Lodging Xospata · Oncology · travel to Kobe, Japan | $9,029 |
| Janssen Scientific Affairs, LLC Sep 23, 2025 | Consulting Fee | $2,503 |
| Sumitomo Pharma America, Inc. Aug 21, 2025 | Consulting Fee | $3,440 |
| Sumitomo Pharma America, Inc. Aug 21, 2025 | Consulting Fee | $2,580 |
| Astellas Pharma Europe LTD Jul 28, 2025 | Consulting Fee Xospata · Oncology | $6,090 |
| Daiichi Sankyo Inc. Jul 9, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $1,250 |
| Astellas Pharma US Inc Jul 8, 2025 | Consulting Fee Cresemba · Infectious Diseases | $3,825 |
| Astellas Pharma US Inc Apr 10, 2025 | Consulting Fee Xospata · Oncology | $4,050 |
| Astellas Pharma US Inc Apr 10, 2025 | Travel and Lodging Xospata · Oncology · travel to Las Vegas, NV | $122 |
| Astellas Pharma US Inc Apr 9, 2025 | Travel and Lodging Xospata · Oncology · travel to Las Vegas, NV | $359 |
| Astellas Pharma US Inc Apr 9, 2025 | Travel and Lodging Xospata · Oncology · travel to Las Vegas, NV | $295 |
| Astellas Pharma US Inc Apr 9, 2025 | Travel and Lodging Xospata · Oncology · travel to Las Vegas, NV | $134 |
| Daiichi Sankyo Inc. Mar 26, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $1,250 |
| Daiichi Sankyo Inc. Mar 19, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $6,250 |
| Daiichi Sankyo Inc. Mar 19, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $1,875 |
| Daiichi Sankyo Inc. Feb 26, 2025 | Travel and Lodging Vanflyta · ONCOLOGY · travel to MIAMI, FL · in-kind | $642 |
| Daiichi Sankyo Inc. Feb 26, 2025 | Travel and Lodging Vanflyta · ONCOLOGY · travel to MIAMI, FL · in-kind | $194 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $317,017 in research payments for these studies, mostly to the institutions running them.
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc. · Recruiting · NCT04988555 - A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AM…
Astellas Pharma Global Development - Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Daiichi Sankyo Inc. · Active, not recruiting · NCT06578247
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.